Consolidated Statements of Operations - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Revenues
Royalty and licensing revenue	$ 11,696,676	$ 13,262,321	$ 18,406,142
Treatment investment revenue	65,641	250,549	39,854
Grant and contract revenue	0	469,307	0
Total Revenue	11,762,317	13,982,177	18,445,996
Operating expenses
General and administrative	5,887,135	11,263,804	6,530,533
Research and development	2,486,514	8,478,817	3,171,599
Royalty expenses	1,408,012	1,491,099	0
License fees	0	13,725,000	0
Selling expenses	438,625	213,897	1,651,099
Total operating expenses	10,220,286	35,172,617	11,353,231
Income (loss) from operations	1,542,031	(21,190,440)	7,092,765
Other income (expense)
Interest income, net	10,401	144,696	19,966
Gain (loss) on foreign exchange	10,027	(48,306)	18,356
Loss on settlement of liability	(13,917)	(49,983)	0
Total other income	6,511	46,407	38,322
Income (loss) before provision for income taxes	1,548,542	(21,144,033)	7,131,087
Provision for income taxes	169,163	51,283	550,474
Net income (loss)	$ 1,379,379	$ (21,195,316)	$ 6,580,613
Income (loss) per share of common stock:
Basic (in shares)	$ 0.66	$ (7.10)	$ 3.27
Diluted (in shares)	$ 0.31	$ (7.10)	$ 2.94
Weighted average common stock outstanding
Basic (in dollars per share)	2,077,663	2,985,335	2,014,540
Diluted (in dollars per share)	4,393,138	2,985,335	2,235,851